Clinical Trials Logo

B-cell Non-Hodgkin's Lymphoma clinical trials

View clinical trials related to B-cell Non-Hodgkin's Lymphoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06314828 Not yet recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL

Start date: May 20, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, single-arm study to evaluate tolerability, safety and efficacy of RJMty19 in adult subjects with r/r B-NHL.

NCT ID: NCT05771883 Not yet recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

Start date: May 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study was to evaluate the safety and efficacy of IMM0306 in combination with lenalidomide in patients with relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma.

NCT ID: NCT05091541 Not yet recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Start date: October 20, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a single-armed, open-label,multicenter Phase 1/2 study to evaluate the safety and efficacy of CT120 in subjects with relapsed/refractory B-cell non-Hodgkin's lymphoma.

NCT ID: NCT03417414 Not yet recruiting - Clinical trials for B Cell Non-Hodgkin's Lymphoma

Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?

Start date: March 1, 2018
Phase: N/A
Study type: Observational

This is an observational cohort study of patients with a new diagnosis of B cell Chronic Lymphocytic Leukemia or B cell Non-Hodgkin's Lymphoma who will receive an anti-CD20 monoclonal antibody treatment during the induction phase of their treatment. Throughout the study, patients will have four blood draws at specified time points throughout the study. The initial blood draw will be analysed test patients for Cytomegalovirus and conduct a g-NK cell analysis. The final three blood draws will be conducted to analyse the g-NK cells at specified time points. The objectives of this study are to: 1) characterize the frequency of CMV (+) and g-NK (+) individuals in the B-NHL and B-CLL populations, 2) Determine changes in circulating g-NK cells during and after anti-CD20 monoclonal antibody containing remission induction chemotherapy and 3) Evaluate whether the presence of g-NK cells improve the outcome of anti-CD20 monoclonal antibody containing remission induction treatment of patients with B-NHL or B-CLL.

NCT ID: NCT03105596 Not yet recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)

Start date: April 11, 2017
Phase: Phase 2
Study type: Interventional

This is a prospective phase II clinical trial to observe the efficacy and safety of Chidamide combined with DICE (Dexamethasone, Ifosfamide, Cisplatin and Etoposide) in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL).